Details for Patent: 8,940,330
✉ Email this page to a colleague
Which drugs does patent 8,940,330 protect, and when does it expire?
Patent 8,940,330 protects ZUBSOLV and is included in one NDA.
This patent has forty-nine patent family members in thirty-one countries.
Summary for Patent: 8,940,330
| Title: | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
| Abstract: | There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain. |
| Inventor(s): | Fischer; Andreas (Uppsala, SE) |
| Assignee: | Orexo AB (Uppsala, SE) |
| Application Number: | 14/127,470 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,940,330 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; Process; |
Drugs Protected by US Patent 8,940,330
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-006 | Oct 4, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-001 | Jul 3, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-005 | Jun 4, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-002 | Jul 3, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-003 | Dec 11, 2014 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Orexo Us Inc | ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242-004 | Dec 11, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,940,330
| PCT Information | |||
| PCT Filed | September 18, 2012 | PCT Application Number: | PCT/GB2012/052303 |
| PCT Publication Date: | March 28, 2013 | PCT Publication Number: | WO2013/041851 |
International Family Members for US Patent 8,940,330
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012311293 | ⤷ Sign Up | |||
| Australia | 2013245546 | ⤷ Sign Up | |||
| Brazil | 112014006356 | ⤷ Sign Up | |||
| Canada | 2834327 | ⤷ Sign Up | |||
| Chile | 2014000575 | ⤷ Sign Up | |||
| China | 103813785 | ⤷ Sign Up | |||
| Colombia | 6960541 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
